Cohance Lifesciences Ltd (NSE:COHANCE)
₹ 455.95 +6.05 (+1.34%) Market Cap: 174.56 Bil Enterprise Value: 176.59 Bil PE Ratio: 165.07 PB Ratio: 4.41 GF Score: 82/100

Suven Pharmaceuticals Ltd Acquisition Of Sapala Organics M&A Call Transcript

Jun 19, 2024 / 12:00PM GMT
Release Date Price: ₹734.4 (-1.88%)
Operator

Ladies and gentlemen, good day and welcome the Suven Pharmaceuticals Limited conference call. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Ms. Cyndrella Carvalho, Head of Investor Relations at Suven Pharmaceuticals Limited. Thank you and over to you, ma'am.

Cyndrella Carvalho;Vaidheesh Annaswamy
Suven Pharmaceuticals Ltd - Head, Investor Relations;Suven Pharmaceuticals Ltd - Executive

Thank you, Darwin. Good evening, everyone. I welcome you all to today's conference call to update on the acquisition of a strategic controlling stake in Sapala Organics. Our management team present here with us today includes Mr. Annaswamy Vaidheesh, Executive Chairman; Dr. V. Prasada Raju, Managing Director; and Mr. Himanshu Agarwal, Chief Financial Officer. Let's dwell into the key highlights of the transaction and (technical difficulty) the floor for Q&A.

Now I invite Mr. Annaswamy Vaidheesh, our Executive Chairman, to share his thoughts on this acquisition.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot